2023 World Conference on Lung Cancer (Posters)-EP06.03. Genomic Landscape of Non-Small Cell Lung Cancer in the Republic of Ireland

Pdf Summary

Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths worldwide, including in Ireland. While treatment options for NSCLC have historically been limited, advances in genomic profiling have led to the identification of actionable genomic alterations that can be targeted with specific treatments. This retrospective study aimed to assess the genomic landscape of NSCLC in Ireland and determine the prevalence of actionable alterations.<br /><br />The study included 2052 patients with NSCLC whose tumors underwent genomic testing using a large panel of genes. The patients were referred from 23 different hospital sites across all four geographic regions of Ireland. The majority of patients (77%) had adenocarcinoma histology, and the median age was 69 years.<br /><br />The study found that 53.4% of patients had identifiable driver oncogene mutations. The most common mutation was KRAS, which was found in 32% of cases. Among the KRAS mutations, the most frequent subtypes were G12C, G12V, and G12D. Other common mutations included EGFR, MET exon 14 skipping, MET amplification, HER2, and BRAF. Fusion genes were detected in 3.8% of patients, including ALK, RET, ROS1, and FGFR3 fusions.<br /><br />Importantly, the study revealed a lower prevalence of ALK, ROS1, and RET fusions compared to similar datasets. Co-alterations, where multiple mutations occurred together, were detected in 5.8% of patients.<br /><br />These findings have important implications for the treatment and design of clinical trials in Ireland. The high prevalence of actionable genomic alterations suggests that targeted therapies may benefit a significant proportion of NSCLC patients. However, the lower prevalence of specific mutations, such as ALK, ROS1, and RET fusions, suggests that alternative treatment strategies may be needed for these patients. Overall, this study provides a comprehensive characterization of the genomic landscape of NSCLC in Ireland and highlights the importance of genomic profiling in guiding treatment decisions.

Asset Subtitle

Rachel Keogh

Meta Tag

Speaker Rachel Keogh

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

Non-small cell lung cancer

NSCLC

cancer-related deaths

genomic profiling

actionable genomic alterations

retrospective study

genomic landscape

prevalence of actionable alterations

KRAS mutation

fusion genes